CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-11). The draft was written by AI, the existence of all 5 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 313 · Search date 2026-07-11 · Methodology v0.6

Calcium D-glucarate,
does it really help with Enhanced liver detoxification and toxin elimination?

30-Second Summary
C
Evidence Grade C · 40 · Safety unknown
A Phase I human trial found a positive enzyme surrogate, but actual toxin elimination and liver-function efficacy were not measured
What the
research shows
A Phase I dose-escalation trial gave healthy smokers and nonsmokers calcium D-glucarate at 1.5 to 9.0 g/day for six weeks and found lower beta-glucuronidase with higher blood D-glucaric acid. However, it was not a randomized placebo-controlled efficacy trial and did not measure elimination of a specified toxin, liver function, symptoms, or clinical outcomes, so this is a very low C based only on a mechanistic surrogate.
What the
ads claim
Advertising may use phrases such as 'phase II liver detoxification,' 'hormone and environmental-toxin elimination,' and 'estrogen detoxification' as if they were specific clinical effects. The public evidence mainly consists of an enzyme-inhibition hypothesis and animal metabolism or tumor models; human toxin removal and health outcomes are not established.
*

Useful facts when choosing a product

  • Calcium D-glucarate is the calcium salt of D-glucaric acid, and the glucarate component rather than calcium is the proposed active part.
  • The Phase I trial used 1.5 to 9.0 g/day over six weeks.
  • Beta-glucuronidase inhibition is a biochemical surrogate and is not equivalent to elimination of a specified toxin or improvement of liver disease.
  • Long-term human safety, effects on enterohepatic recirculation of medicines and hormones, and pregnancy or lactation data are limited.
Gap Measurement · Verdict 313 · C 40
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

A Phase I trial gave healthy male and female smokers and nonsmokers escalating doses of calcium D-glucarate from 1.5 to 9.0 g/day over six weeks. Blood D-glucaric acid rose with dose, beta-glucuronidase was consistently suppressed at measurements every two weeks, and no unusual toxicity was reported even at the highest dose. The study was not a randomized placebo-controlled efficacy trial and did not measure excretion of a specified toxin, clinical liver function, symptoms, or liver-disease outcomes. Human evidence therefore exists, ruling out an unknown rating, but it supports only a very low C based on a mechanistic surrogate.

02

Why this is classified as C (40)

A six-week Phase I dose-escalation trial in healthy smokers and nonsmokers used 1.5 to 9.0 g/day and found lower beta-glucuronidase with higher blood D-glucaric acid, so the rating is not unknown. However, it was not a randomized placebo-controlled efficacy trial and did not measure specified-toxin elimination, liver function, symptoms, or clinical outcomes. Mechanistic-surrogate evidence alone supports a very low C with 40 points.

Counterpoint. A measurable mechanistic signal exists in humans and can support future placebo-controlled excretion and clinical trials, but it does not establish actual liver detoxification or toxin-elimination efficacy.

Rejudgment record. Reassessment (cross-check reflected) — A six-week Phase I dose-escalation trial in healthy smokers and nonsmokers at 1.5 to 9.0 g/day found lower beta-glucuronidase and higher blood D-glucaric acid, but it was nonrandomized and uncontrolled and did not measure specified-toxin elimination, liver function, symptoms, or clinical outcomes

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Beta-glucuronidase mechanistic surrogateCLowered in a six-week Phase I dose-escalation trial at 1.5 to 9.0 g/day
Actual liver detoxification and toxin elimination?Clinical efficacy outcomes were not measured

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Walaszek Z et al. 2002 Phase IPhase I dose-escalation human trial in healthy smokers and nonsmokers; not randomized or placebo-controlledNot stated in the public abstract or reviewBlood D-glucaric acid and beta-glucuronidase at baseline and every two weeksCalcium D-glucarate at 1.5 to 9.0 g/day for six weeks increased blood D-glucaric acid and consistently lowered beta-glucuronidase, but toxin elimination, liver function, and symptoms were not measured.Key human mechanistic-surrogate evidence
Dwivedi C et al. 1990Animal pharmacology and food-analysis studyUnknownSerum, liver, lung, and intestinal beta-glucuronidase and food glucaric acidCalcium glucarate inhibited beta-glucuronidase activity in animal tissues.Key preclinical evidence
Walaszek Z et al. 1997Radiolabeled pharmacokinetic animal studyUnknownAbsorption, tissue distribution, metabolism, and excretionThe metabolism of an oral D-glucarate salt and formation of D-glucaro-1,4-lactone were evaluated in rats.Preclinical mechanism
Maruti SS et al. 2008Controlled crossover human feeding trial63Supported by the U.S. National Institutes of HealthHigh fruit-and-vegetable diet and serum beta-glucuronidaseThe whole plant-food diet was evaluated; calcium D-glucarate alone and a clinical toxin-elimination effect were not tested.Indirect, ingredient mismatch
§

Receipt — 5 References

All 5 cited sources were verified for existence at the original page (as of 2026-07-11).

Walaszek Z, Raich P, Hanausek M, Szemraj J, Narog M, Slaga TJ. Potential role of D-glucaric acid in lung cancer prevention. Proc Am Assoc Cancer Res. 2002;43:306. Phase I trial summarized in Hanausek M, Walaszek Z, Slaga TJ. Detoxifying cancer causing agents to prevent cancer. Integr Cancer Ther. 2003;2(2):139-144. DOI: 10.1177/1534735403002002005.
checked
Dwivedi C, Heck WJ, Downie AA, Larroya S, Webb TE. Effect of calcium glucarate on beta-glucuronidase activity and glucarate content of certain vegetables and fruits. Biochem Med Metab Biol. 1990;43(2):83-92. PMID: 2346674. DOI: 10.1016/0885-4505(90)90012-P.
checked
Walaszek Z, Szemraj J, Narog M, Adams AK, Kilgore J, Sherman U, Hanausek M. Metabolism, uptake, and excretion of a D-glucaric acid salt and its potential use in cancer prevention. Cancer Detect Prev. 1997;21(2):178-190. PMID: 9101079.
checked
Maruti SS, Chang JL, Prunty JA, Bigler J, Schwarz Y, Li SS, Li L, King IB, Potter JD, Lampe JW. Serum beta-glucuronidase activity in response to fruit and vegetable supplementation: a controlled feeding study. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1808-1812. PMID: 18628435. DOI: 10.1158/1055-9965.EPI-07-2660.
checked
Calcium-D-glucarate. Altern Med Rev. 2002;7(4):336-339. PMID: 12197785.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none

Cite this verdict

Calcium D-glucarate × enhanced liver detoxification and toxin elimination Evidence Grade C card
[Chamgap] Calcium D-glucarate × enhanced liver detoxification and toxin elimination — Evidence Grade C·40. 5 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/liver/calcium-d-glucarate-liver-detoxification/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.